About this Journal Submit a Manuscript Table of Contents
ISRN Immunology
Volume 2013 (2013), Article ID 548312, 8 pages
http://dx.doi.org/10.1155/2013/548312
Clinical Study

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Patients with Severe Systemic-Onset Juvenile Idiopathic Arthritis Followed for 12 Months

1Federal State Budgetary Institution “Scientific Center of Children’s Health,” Russian Academy of Medical Sciences, Moscow 119991, Russia
2I. M. Sechenov First Moscow State Medical University, Moscow 119991, Russia

Received 17 June 2013; Accepted 11 July 2013

Academic Editors: A. Boon, I. Hellstrom, and E. K. Kapsogeorgou

Copyright © 2013 E. I. Alexeeva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. E. Petty, T. R. Southwood, P. Manners et al., “International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,” The Journal of Rheumatology, vol. 31, no. 2, pp. 390–392, 2004. View at Scopus
  2. C. Lomater, V. Gerloni, M. Gattinara, J. Mazzotti, R. Cimaz, and F. Fantini, “Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years,” The Journal of Rheumatology, vol. 27, no. 2, pp. 491–496, 2000. View at Scopus
  3. A. Ravelli and A. Martini, “Juvenile idiopathic arthritis,” The Lancet, vol. 369, no. 9563, pp. 767–778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Woo, T. R. Southwood, A. M. Prieur, et al., “Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis,” Arthritis & Rheumatism, vol. 43, pp. 1849–1857, 2000.
  5. F. De Benedetti and A. Martini, “Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?” The Journal of Rheumatology, vol. 25, no. 2, pp. 203–207, 1998. View at Scopus
  6. F. De Benedetti, M. Massa, P. Robbioni, A. Ravelli, G. R. Burgio, and A. Martini, “Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 34, no. 9, pp. 1158–1163, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. F. De Benedetti, P. Pignatti, V. Gerloni et al., “Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis,” The Journal of Rheumatology, vol. 24, no. 7, pp. 1403–1409, 1997. View at Scopus
  8. F. De Benedetti, T. Alonzi, A. Moretta et al., “Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation,” The Journal of Clinical Investigation, vol. 99, no. 4, pp. 643–650, 1997. View at Scopus
  9. F. De Benedetti, N. Rucci, A. Del Fattore et al., “Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system,” Arthritis and Rheumatism, vol. 54, no. 11, pp. 3551–3563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Cazzola, L. Ponchio, F. De Benedetti et al., “Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis,” Blood, vol. 87, no. 11, pp. 4824–4830, 1996. View at Scopus
  11. M. M. Schoels, D. Van Der Heijde, F. C. Breedveld, et al., “Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement,” Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 583–589, 2013.
  12. G. Horneff, F. D. De Bock, I. Foeldvari et al., “Safety and efficacy of combination of Etanercept and methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (jia): preliminary data from the german JIA registry,” Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 519–525, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. H. M. Prince, M. Twilt, R. ten Cate et al., “Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch National Register,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 635–641, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Yokota, T. Imagawa, and T. Miyamae, “Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536],” Annals of the Rheumatic Diseases, vol. 68, supplement 3, p. 715, 2009.
  15. Y. Inaba, C. Aoki, and R. Ozawa, “Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555],” Annals of the Rheumatic Diseases, vol. 68, supplement 3, p. 720, 2009.
  16. S. Yokota, T. Imagawa, M. Mori et al., “Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial,” The Lancet, vol. 371, no. 9617, pp. 998–1006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Yokota, T. Miyamae, T. Imagawa et al., “Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 52, no. 3, pp. 818–825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Kaneko, T. Imagawa, and T. Kishi, “Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548],” Annals of the Rheumatic Diseases, vol. 68, supplement 3, p. 719, 2009.
  19. F. De Benedetti, H. I. Brunner, N. Ruperto, et al., “Randomized trial of tocilizumab in systemic Juvenile idiopathic arthritis,” The New England Journal of Medicine, vol. 367, no. 25, pp. 2385–2395, 2012.
  20. S. Yokota, T. Tanaka, and T. Kishimot, “Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis,” Therapeutic Advances in Musculoskeletal Disease, vol. 4, no. 6, pp. 387–397, 2012.
  21. R. Russo and M. Katsicas, “Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy,” Pediatric Rheumatology, vol. 9, supplement 1, article 186, 2011.
  22. S. Sawhney and M. Aggarwal, “Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India,” Pediatric Rheumatology, vol. 10, supplement 1, article A49, 2012.
  23. J. S. Smolen, M. M. Schoels, and N. Nishimoto, “Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions,” Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 482–492, 2013.
  24. E. Alexeeva, R. Denisova, S. Valieva et al., “Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis,” Pediatric Rheumatology, vol. 9, supplement 1, article P202, 2011.
  25. C. A. Wallace, E. H. Giannini, B. Huang, et al., “American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis,” Arthritis Care & Research, vol. 63, no. 7, pp. 929–936, 2011.
  26. M. H. Schiff, J. M. Kremer, A. Jahreis, E. Vernon, J. D. Isaacs, and R. F. van Vollenhoven, “Integrated safety in tocilizumab clinical trials,” Arthritis Research and Therapy, vol. 13, no. 5, article R141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Davi, B. Lattanzi, S. Rosina, et al., “Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis,” Pediatric Rheumatology, vol. 9, supplement 1, article P101, 2011.